Key Highlights

  • Second-quarter revenue rose 13% and adjusted EBITDA rose 32%.
  • Net income rose 335%.
  • Trailing-twelve-month revenue is $175.17 million, down 6.9%.
  • Three analysts rate the stock Strong Buy with a $8.75 average target.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) has a market value near $557 million. The company has been attending investor conferences this month, and the focus is on results and strategy, including expansion into non-aesthetic healthcare and overseas markets.

Latest Company Context

SBC reported second-quarter 2026 results on August 13 under the headline "Restructuring Complete, Growth Reaccelerates." The company reported revenue up 13% year over year, net income up 335% and adjusted EBITDA up 32%. Trailing-twelve-month revenue is $175.17 million (down 6.9%), net income is $49.03 million and EPS is $0.48. Full-year 2025 revenue was $173.61 million, down 15.5%, with earnings of $50.99 million. Those figures indicate that the recent quarter marked a turn after a weaker year. No dividend is listed. Investor conference transcripts from October cover expansion into non-aesthetic healthcare and overseas markets. A company-sponsored research firm raised its target to $11.00 in August; sponsored research should be read with that relationship in mind.

Key Business Drivers

The business supports aesthetic medical clinics, so demand depends on consumer spending and clinic-network performance. Management's stated push into non-aesthetic healthcare and overseas markets could diversify revenue but may also carry execution and regulatory risk. The year-over-year jump in net income may partly reflect comparisons with restructuring-affected periods. Three analysts rate the stock Strong Buy with a $8.75 average target.

What Investors Should Watch

The next earnings date is estimated at November 13, 2026. Investors may watch whether growth at the 13% revenue pace is sustained, how adjusted EBITDA develops, and whether the company provides concrete targets for new markets. Further catalysts could include investor-conference messaging, new clinic openings or partnerships, and any disclosures on cash and capital allocation.

A Turn After a Weaker Year, With Expansion Plans Ahead

SBC's recent quarter marked a turn after a weaker 2025, with revenue growth and a strong rise in net income. A company-sponsored research firm's $11.00 target should be read with that relationship in mind.